8-K - Acurx Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Acurx Pharmaceuticals, Inc. approved voluntary 10% base salary reductions for key executives and cash compensation for non-employee directors effective April 1, 2026, and announced a new open-label pilot trial for ibezapolstat in up to 20 patients with multiply-recurrent C. difficile infection, with start-up later this month and first enrollment in Q4 2026.

Key Takeaways

1Compensation Committee approved 10% base salary reductions effective April 1, 2026: David P. Luci (President/CEO) to $495,000; Robert J. DeLuccia (Executive Chairman) to $495,000; Robert G. Shawah (CFO) to $360,000.

210% reduction to cash components of non-employee director compensation effective April 1, 2026.

3New open-label pilot trial in up to 20 patients with at least two recurrences of CDI within past 12 months; trial start-up later this month, first-patient enrollment Q4 2026.

4Data from pilot to inform planned active-controlled Phase 3 registration trial in rCDI.

5Plans to seek FDA approval under LPAD pathway for treatment and prevention of rCDI following successful Phase 3.

6Exhibit 99.1 press release filed detailing ibezapolstat rCDI program.

Current Report Details

Event Type

Management Change

Other Event

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 9, 2

Management Change

$495.0K$495.0K$360.0K

8.01

. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 99.1 Press Relea

Exhibits Only

Source Document

Executive & Director Changes

David P. Luci

President and Chief Executive Officer

Salary Reduction

Effective: 2026-04-01

Robert J. DeLuccia

Executive Chairman

Salary Reduction

Effective: 2026-04-01

Robert G. Shawah

Chief Financial Officer

Salary Reduction

Effective: 2026-04-01

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1